(4R,6R)-6-(2-hydroxyethoxy)-2-(hydroxymethyl)oxane-3,4-diol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (4R,6R)-6-(2-hydroxyethoxy)-2-(hydroxymethyl)oxane-3,4-diol
• 化学式: C₈H₁₆O₆
• 分子量: 208.21
• InChiKey: CQNVPRWPCOVHPF-RYVOCIFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  99.4
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• [EN] CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS<br/>[FR] CONJUGUÉS POUR TRAITER LES MALADIES PROVOQUÉES PAR DES CELLULES EXPRIMANT PSMA
  申请人：ENDOCYTE INC

  公开号：WO2014078484A1

  公开（公告）日：2014-05-22

  The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

  本发明涉及对病原细胞群体进行诊断、成像和/或治疗。具体来说，本发明涉及利用能够靶向PSMA表达细胞的化合物对由PSMA表达细胞引起的疾病，如前列腺癌细胞，进行诊断、成像和/或治疗。
• [EN] DUAL DISULFIDE DRUG CONJUGATES<br/>[FR] CONJUGUÉS DE MÉDICAMENTS À DEUX GROUPES DISULFURE
  申请人：ENDOCYTE INC

  公开号：WO2016168471A1

  公开（公告）日：2016-10-20

  The invention described herein pertains to dual disulfide drug conjugates. In particular, the invention described herein pertains to dual disulfide drug conjugates that target the folate receptor for delivery of conjugated drugs to a mammalian recipient. Also described are methods of making and using dual disulfide drug conjugates.

  本发明涉及双二硫醚药物共轭物。具体而言，本发明涉及双二硫醚药物共轭物，其靶向叶酸受体，用于将共轭药物传递给哺乳动物接受者。还描述了制备和使用双二硫醚药物共轭物的方法。
• [EN] METHODS FOR TREATING CANCER USING COMBINATION THERAPIES<br/>[FR] MÉTHODES POUR TRAITER LE CANCER AU MOYEN DE POLYTHÉRAPIES
  申请人：ENDOCYTE INC

  公开号：WO2014085575A1

  公开（公告）日：2014-06-05

  Described are methods, uses, and kits for utilizing a targeted ligand conjugate in combination with a thiol inhibitor or a system xc-inhibitor for the treatment of cancer or inflammation. Also described are invitro assays utilizing a targeted ligand conjugate in combination with a thiol inhibitor or a system xc- inhibitor.